| Name | Title | Contact Details |
|---|
St. Mary`s Healthcare offers a continuum of services designed to fulfill the total healthcare needs of the community, while being the lowest cost provider. In addition to our 143 bed hospital, a 160 bed nursing home and a 10 bed acute rehabilitation unit, St. Mary`s provides highly accessible healthcare through its seven offsite primary care centers and behavioral health service locations throughout two counties. We treat more than 290,000 outpatient visits a year. Founded by the Sisters of St. Joseph of Carondelet in 1903, and as a member of Ascension since 2002, St. Mary`s is dedicated to improving the health of the community with special attention to the poor and underserved. By addressing the spiritual, social, emotional and physical needs of our patients, we strive to provide an exceptional patient experience and a model community for our associates and medical staff.
SkinTreet is a Peachtree City, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NutraOne was created for two groups of people: our customers and our retailers. Our mission is to always provide the quality product you demand at the most affordable price possible.
Stanford Hospital and Clinics is located on the northern end of the Stanford University campus in Palo Alto, California.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.